Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • NCD 2025
NET Nurse
Donate

Home » Advocacy » ENETS session – High grade classification

ENETS session – High grade classification

  • March 26, 2019

(by Meredith Cummins, NSW Project Officer)

The 16th ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumour Disease was a wonderful opportunity to network internationally and gain knowledge and insight into the great work being done in this field. There were so many fabulous sessions, so many that it was difficult to report on them all. The session below was part of the ENETs / European Society of Pathology (ESP) New Classification / Making Sense of High-grade Neoplasms. Within this session Dr Jean – Yves Scoazec from France presented Pulmonary and Digestive High Grade NENs – Where are they similar? The following highlights the grading and a conclusion of the grading. So much work is being done to better define the respective NETs so that treatment can be customized for better management.

WHO classification of digestive NENs (2019) is divided into-

  • Neuroendocrine tumour G1 – differentiation  – well differentiated, mitotic index ,2 mitoses / 2mm2, Ki 67 Index <= 2% (Low Grade)
  • Neuroendocrine tumour G2 – differentiation – well differentiated ,mitotic index 2-20 mitoses / 2mm2, Ki 67 Index – 3-20 % (Intermediate Grade)
  • Neuroendocrine G3 – differentiation – well differentiated, mitotic index  20 mitoses / 2 mm2, Ki 67 index >20% (High Grade)
  •  Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index >20% (High to very High Grade)
  • Small cell neuroendocrine carcinoma – differentiation  – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index  > 20% (High to very High Grade)

Next WHO classification of Lung NENs (20..)

  • Typical Carcinoid – differentiation  – well differentiated, necrosis  – absent, Mitotic index , 2 mitoses / 10HPF (2mm2)( Low Grade)
  • Atypical carcinoid – well differentiated, necrosis – possible, focal, mitotic index – 2-10 mitoses / 10HPF (2mm2) (Intermediate Grade)
  • Supracarcinoid – differentiation – well differentiated – (High Grade)
  • Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, necrosis – frequent, extensive, mitotic index  >10mitoses/ 10HPF (2mm2) – (High to very High Grade)
  • Small Cell neuroendocrine carcinoma – differentiation  – poorly differentiated, necrosis  – frequent, extensive, mitotic index > 10 mitoses / 10HPF (2mm2) – (High to very High Grade)

So in conclusion :

  • Lung and digestive high grade NENs share some similarities but they also express site specific feature
  • High grade NETs exist in both the digestive system and the lung: they require an accurate diagnosis and probably, an adapted treatment
  • Small Cell neuroendocrine carcinoma is a distinctive entity
  • Large Cell neuroendocrine carcinoma is a diverse category with a need for a reevaluation of our diagnostic and therapeutic approaches

Share this post

Recent posts

Sydney NET Patient Forum Brings Together Patients and Clinicians

October 28, 2025

Patient and Consumer Roundtable on Comparator Selection in HTA

October 27, 2025

Racing for a Cure 2025

October 27, 2025

NECA Highlights Gaps in Government’s Senate Inquiry Response

October 16, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousPetition update
NextLet’s BE FAIR with government cancer fundingNext

Related Posts

Patient and Consumer Roundtable on Comparator Selection in HTA

On Monday 27 October our CEO attended a face to face Patient and Consumer Roundtable in Canberra with 10 other not-for-profit organisation. The Roundtable was

NECA Highlights Gaps in Government’s Senate Inquiry Response

After 458 days of waiting, the Government finally released its response to the Senate  Inquiry into Rare and Less Common Cancers, including Neuroendocrine Cancer, on

PCPA Cancer Summit

  The Private Cancer Physicians of Australia (PCPA) hosted its Annual Meeting: Cancer Summit 2025 in Sydney on 13 September, bringing together clinicians, researchers, and

SCAN 2025 is now open – we need your voice

SCAN 2025 is now open – we need your voice.  As a proud member of the International Neuroendocrine Cancer Alliance (INCA), NeuroEndocrine Cancer Australia is excited

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin